The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Abstract
MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [32]
In the citing paper
“Nutlin-3a had the strongest activity, and its binding activity with MDM2 reached 90 nM.”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“At 200 mg/kg, twice a day, 20 days after oral administration of Nutlin-3a, the tumor growth inhibition rate reached 90%, with no obvious side effects [20].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [20]
In the citing paper
“Moreover, others have shown that inhibition of MDM2 binding to p53 or p73α appears to be more effective at promoting p53- and p73α-mediated apoptosis in cancer cells compared with normal cells.19,45”
From Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist (2017) · cites this paper as [45]
In the citing paper
“Nutlin-3a is a small molecule, which binds to the N-terminal hydrophobic pocket of Mdm2 and blocks protein-protein interactions (PPIs) between Mdm2 and p53 (10).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [10]
In the citing paper
“It has been reported that a consequence of Nutlin treatment is elevated Mdm2 protein levels, and this occurs in cells with or without p53 (6,8).”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nutlin-3 is a small molecule inhibitor of Mdm2/p53 interaction that can induce apoptosis in cancer cells through activation of p53.”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [6]
In the citing paper
“Nonmalignant tissues tolerate inhibition of Mdm2, and no overt toxicity was observed in preclinical in vivo models.9,11”
From Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death (2013) · cites this paper as [9]
In the citing paper
“For example, small molecule antagonism of the Mdm2–p53 interaction promotes p53-dependent tumor regression in murine models [102,103].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [103]
In the citing paper
“Small-molecule PPI antagonists that disrupt the p53–MDM2 interaction have been identified, including nutlin 3a96 and MI-219 (Ref. 97).”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [96]
In the citing paper
“To utilize MDM2 for the PROTAC system, the discovery of nutlins, small molecules that bind MDM2 at the p53 interaction interface, was a crucial step [66].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [66]
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Requirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
Flagged first, then by citations
Research works printed but not linked: 3
- D. Freedman, A. J. Levine, Cell. Mol. Life Sci.5, 96 (1999).
- R. Zhang, H. Wang, Methods Mol. Med.85, 205 (2003).
- L. T. Vassilevet al., Anticancer Drug Des.13, 359 (2001).
Cited by
Sorted by citations
Items 401–500 of 1,103
Targeting the p53 signaling pathway in cancer therapy – the promises, challenges and perils
Stegh, A. H. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.643299 · Cited by 198
The RING finger protein family in health and disease
Cai, C., Tang, Y., Zhai, J., & Zheng, C. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01152-2 · Cited by 204
Systematic Analysis of Helical Protein Interfaces Reveals Targets for Synthetic Inhibitors
Jochim, A. L., & Arora, P. S. (2010) · ACS Chemical Biology · doi:10.1021/cb1001747 · Cited by 191
Cardote, T. A. F., & Ciulli, A. (2015) · ChemMedChem · doi:10.1002/cmdc.201500450 · Cited by 189
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
Li, Q., & Lozano, G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 197
Warso, M. A., Richards, J. M., Mehta, D., Christov, K. T., Schaeffer, C., Bressler, L. R., Yamada, T., Majumdar, D., Kennedy, S., Beattie, C. W., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.74 · Cited by 190
McNeil, E. M., & Melton, D. W. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks818 · Cited by 195
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189
Outcomes of p53 activation - spoilt for choice
Vousden, K. H. (2006) · Journal of Cell Science · doi:10.1242/jcs.03293 · Cited by 192
IRF4: Immunity. Malignancy! Therapy?
Shaffer, A. L., Emre, N. C. T., Romesser, P. B., & Staudt, L. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1845 · Cited by 197
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors
Brummelkamp, T. R., Fabius, A. W. M., Mullenders, J., Madiredjo, M., Velds, A., Kerkhoven, R. M., Bernards, R., & Beijersbergen, R. L. (2006) · Nature Chemical Biology · doi:10.1038/nchembio774 · Cited by 190
Krummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187
Mdmx as an essential regulator of p53 activity
Marine, J., & Jochemsen, A. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.151 · Cited by 189
Recent Advances in p53 Research and Cancer Treatment
Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 191
The molecular programme of tumour reversion: the steps beyond malignant transformation
Telerman, A., & Amson, R. B. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2589 · Cited by 196
Targeting Programmed Cell Death Using Small‐Molecule Compounds to Improve Potential Cancer Therapy
Ke, B., Tian, M., Li, J., Liu, B., & He, G. (2016) · Medicinal Research Reviews · doi:10.1002/med.21398 · Cited by 190
The roles of E3 ubiquitin ligases in cancer progression and targeted therapy
Sampson, C., Wang, Q., Otkur, W., Zhao, H., Lu, Y., Liu, X., & Piao, H. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1204 · Cited by 193
Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair
Bolderson, E., Richard, D. J., Zhou, B. S., & Khanna, K. K. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0096 · Cited by 194
Complicating the complexity of p53
Yee, K. S. Y., & Vousden, K. H. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi122 · Cited by 190
Heinemann, A., Zhao, F., Pechlivanis, S., Eberle, J., Steinle, A., Diederichs, S., Schadendorf, D., & Paschen, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1977 · Cited by 189
Kolev, V. N., Mandinova, A., Guinea‐Viniegra, J., Hu, B., Lefort, K., Lambertini, C., Neel, V., Dummer, R., Wagner, E. F., & Dotto, G. P. (2008) · Nature Cell Biology · doi:10.1038/ncb1750 · Cited by 187
Brooks, C. L., & Gu, W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.05.022 · Cited by 186
Wu, X., He, C., Wu, Y., & Chen, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.10.016 · Cited by 189
p53-dependent Induction of PVT1 and miR-1204
Barsotti, A. M., Beckerman, R., Laptenko, O., Huppi, K. E., Caplen, N. J., & Prives, C. L. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.322875 · Cited by 189
Targeting protein–protein interactions: Lessons from p53/MDM2
Murray, J. K., & Gellman, S. H. (2007) · Biopolymers · doi:10.1002/bip.20741 · Cited by 190
53BP1 Integrates DNA Repair and p53-Dependent Cell Fate Decisions via Distinct Mechanisms
Cuella-Martin, R., Oliveira, C., Lockstone, H. E., Snellenberg, S., Grolmusova, N., & Chapman, J. R. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.08.002 · Cited by 194
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182
FOXM1 (Forkhead box M1) in Tumorigenesis
Wierstra, I. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 190
Oliver, C. L., Miranda, M. B., Shangary, S. K., Land, S. R., Wang, S., & Johnson, D. E. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.23.4.1 · Cited by 182
p53 regulates Period2 expression and the circadian clock
Miki, T., Matsumoto, T., Zhao, Z., & Lee, C. C. (2013) · Nature Communications · doi:10.1038/ncomms3444 · Cited by 195
Trosset, J., Dalvit, C., Knapp, S., Fasolini, M., Veronesi, M., Mantegani, S., Gianellini, L. M., Catana, C., Sundström, M., Stouten, P. F. W., et al. (2006) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20955 · Cited by 182
Nikulenkov, F., Spinnler, C., Li, H., Tonelli, C., Shi, Y., Turunen, M. M., Kivioja, T., Ignatiev, I., Kel, A. E., Taipale, J., et al. (2012) · Cell Death and Differentiation · doi:10.1038/cdd.2012.89 · Cited by 181
Zahnow, C. A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001033 · Cited by 180
Disorder and residual helicity alter p53-Mdm2 binding affinity and signaling in cells
Borcherds, W. M., Theillet, F., Katzer, A., Finzel, A., Mishall, K. M., Powell, A. T., Wu, H., Manieri, W., Dieterich, C., Selenko, P., et al. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1668 · Cited by 187
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction
Yu, S., Qin, D., Shangary, S., Chen, J., Wang, G., Ding, K., McEachern, D., Qiu, S., Nikolovska-Coleska, Z., Miller, R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901400z · Cited by 180
Chromenes: Potential New Chemotherapeutic Agents for Cancer
Patil, S. A., Patil, R., Pfeffer, L. M., & Miller, D. D. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.126 · Cited by 179
Systematic approaches to identify E3 ligase substrates
Iconomou, M., & Saunders, D. N. (2016) · Biochemical Journal · doi:10.1042/bcj20160719 · Cited by 180
Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma
Stühmer, T., Chatterjee, M., Hildebrandt, M., Herrmann, P., Gollasch, H., Gerecke, C., Theurich, S., Cigliano, L., Manz, R. A., Daniel, P. T., et al. (2005) · Blood · doi:10.1182/blood-2005-04-1489 · Cited by 180
Self-citationMedema, R. H., & Macůrek, L. (2011) · Oncogene · doi:10.1038/onc.2011.451 · Cited by 190
The ubiquitin system, disease, and drug discovery
Petroski, M. D. (2008) · BMC Biochemistry · doi:10.1186/1471-2091-9-s1-s7 · Cited by 184
Targeting Apoptosis Pathways for New Cancer Therapeutics
Bai, L., & Wang, S. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-010713-141310 · Cited by 179
Expanding the Number of ‘Druggable’ Targets: Non‐Enzymes and Protein–Protein Interactions
Makley, L. N., & Gestwicki, J. E. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12066 · Cited by 183
Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
Micel, L. N., Tentler, J. J., Smith, P. G., & Eckhardt, G. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0958 · Cited by 178
Stapled Peptides Inhibitors: A New Window for Target Drug Discovery
Ali, A. M., Atmaj, J., Oosterwijk, N. V., Groves, M. R., & Dömling, A. S. S. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.012 · Cited by 180
Wang, Y., Vera, C. I. R., & Lin, Q. (2007) · Organic Letters · doi:10.1021/ol7017328 · Cited by 176
Drugs for ‘protein clouds’: targeting intrinsically disordered transcription factors
Dunker, A. K., & Uversky, V. N. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.09.005 · Cited by 186
Universal Screening Methods and Applications of ThermoFluor®
Cummings, M. D., Farnum, M. A., & Nelen, M. I. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106292746 · Cited by 175
Targeting Protein Serine/Threonine Phosphatases for Drug Development
McConnell, J. L., & Wadzinski, B. E. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.053140 · Cited by 175
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 176
Sadowsky, J., Fairlie, W. D., Hadley, E. B., Lee, H., Umezawa, N., Nikolovska‐Coleska, Z., Wang, S., Huang, D. C. S., Tomita, Y. A., & Gellman, S. H. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0662523 · Cited by 182
Protein–protein interactions and cancer: small molecules going in for the kill
Arkin, M. R. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.03.001 · Cited by 176
p53 Activation by Small Molecules: Application in Oncology
Vassilev, L. T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058174k · Cited by 174
Self-citationRinaldo, C., Prodosmo, A., Mancini, F., Iacovelli, S., Sacchi, A., Moretti, F., & Soddu, S. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.008 · Cited by 175
Phan, J., Li, Z., Kasprzak, A., Li, B., Sebti, S., Guida, W., Schönbrunn, E., & Chen, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073056 · Cited by 173
Choi, M., Shi, J., Jung, S. H., Chen, X. X., & Cho, K. (2012) · Science Signaling · doi:10.1126/scisignal.2003363 · Cited by 170
Dual-Site Regulation of MDM2 E3-Ubiquitin Ligase Activity
Wallace, M., Worrall, E. G., Pettersson, S., Hupp, T. R., & Ball, K. L. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.029 · Cited by 172
Cdc25 Phosphatases: Structure, Specificity, and Mechanism
Rudolph, J. (2007) · Biochemistry · doi:10.1021/bi700026j · Cited by 173
The regulation of MDM2 oncogene and its impact on human cancers
Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 181
CRISPR-Cas9D10A nickase-based genotypic and phenotypic screening to enhance genome editing
Chiang, T.-W. W., le Sage, C., Larrieu, D., Demir, M., & Jackson, S. P. (2016) · Scientific Reports · doi:10.1038/srep24356 · Cited by 171
Sadowsky, J., Schmitt, M. A., Lee, H., Umezawa, N., Wang, S., Tomita, Y. A., & Gellman, S. H. (2005) · Journal of the American Chemical Society · doi:10.1021/ja053678t · Cited by 173
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX
Uldrijan, S., Pannekoek, W., & Vousden, K. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601469 · Cited by 170
A network medicine approach to human disease
Zanzoni, A., Soler‐López, M., & Aloy, P. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.03.001 · Cited by 172
PAC-1 Activates Procaspase-3 in Vitro through Relief of Zinc-Mediated Inhibition
Peterson, Q. P., Goode, D. R., West-Szymanski, D. C., Ramsey, K. N., Lee, J. J. Y., & Hergenrother, P. J. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.03.003 · Cited by 171
p53 and NF-κB Coregulate Proinflammatory Gene Responses in Human Macrophages
Lowe, J. M., Menéndez, D., Bushel, P. R., Shatz, M., Kirk, E. L., Troester, M. A., Garantziotis, S., Fessler, M. B., & Resnick, M. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1070 · Cited by 176
Kodama, T., Takehara, T., Hikita, H., Shimizu, S., Shigekawa, M., Tsunematsu, H., Li, W. S., Miyagi, T., Hosui, A., Tatsumi, T., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44957 · Cited by 175
Molecular signatures associated with ZIKV exposure in human cortical neural progenitors
Zhang, F., Hammack, C., Ogden, S. C., Cheng, Y., Lee, E. M., Wen, Z., Qian, X., Nguyen, H. N., Li, Y., Yao, B., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw765 · Cited by 176
E3 ubiquitin ligases in cancer and implications for therapies
Wang, D., Ma, L., Wang, B., Liu, J., & Wei, W. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9703-z · Cited by 174
Enge, M., Bao, W., Hedström, E., Jackson, S. P., Moumen, A., & Selivanova, G. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.019 · Cited by 172
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
Between a rock and a hard place?
Whitty, A., & Kumaravel, G. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0306-112 · Cited by 171
Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Emerging classes of protein–protein interaction inhibitors and new tools for their development
Pagliaro, L., Felding, J., Audouze, K., Nielsen, S. J., Terry, R. B., Krog-Jensen, C., & Butcher, S. (2004) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2004.06.006 · Cited by 174
Parks, D. J., LaFrance, L. V., Calvo, R. R., Milkiewicz, K. L., Gupta, V., Lattanze, J., Ramachandren, K., Carver, T. E., Petrella, E. C., Cummings, M. D., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.11.009 · Cited by 173
Chu, W. K., Choi, H. L., Bhat, A., & Jhanji, V. (2020) · Eye · doi:10.1038/s41433-020-0786-3 · Cited by 174
The emerging roles of MAPK-AMPK in ferroptosis regulatory network
Wang, X., Tan, X., Zhang, J., Wu, J., & Shi, H. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01170-9 · Cited by 178
The role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
Bakan, A., Nevins, N., Lakdawala, A. S., & Bahar, İ. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300117j · Cited by 167
PROTACs– a game-changing technology
Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., ter Brake, F., Essa, K., & Dömling, A. S. S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 171
Limiting the power of p53 through the ubiquitin proteasome pathwayPreprint
Pant, V., & Lozano, G. (2014) · Genes & Development · doi:10.1101/gad.247452.114 · Cited by 170
Pro-proliferative FoxM1 is a target of p53-mediated repression
Barsotti, A. M., & Prives, C. L. (2009) · Oncogene · doi:10.1038/onc.2009.282 · Cited by 163
The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets Serious
Popowicz, G. M., Dömling, A. S. S., & Holak, T. A. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201003863 · Cited by 170
Koblish, H. K., Zhao, S., Franks, C. F., Donatelli, R. R., Tominovich, R. M., LaFrance, L. V., Leonard, K. A., Gushue, J. M., Parks, D. J., Calvo, R. R., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0199 · Cited by 167
Structure-Based Design of Novel Inhibitors of the MDM2–p53 Interaction
Rew, Y., Sun, D., de Turiso, F. G.-L., Bartberger, M. D., Beck, H. P., Canon, J. R., Chen, A., Chow, D. T., Deignan, J., Fox, B. M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300354j · Cited by 170
Stabilization of protein-protein interactions in drug discovery
Andrei, S. A., Sijbesma, E., Hann, M. M., Davis, J., O’Mahony, G., Perry, M. W. D., Karawajczyk, A., Eickhoff, J., Brunsveld, L., Doveston, R. G., et al. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1346608 · Cited by 166
AirID, a novel proximity biotinylation enzyme, for analysis of protein–protein interactions
Kido, K., Yamanaka, S., Nakano, S., Motani, K., Shinohara, S., Nozawa, A., Kosako, H., Ito, S., & Sawasaki, T. (2020) · eLife · doi:10.7554/elife.54983 · Cited by 164
Hdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme
England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163
Ambrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163
Self-citationThe proteasome and its role in the degradation of oxidized proteins
Jung, T., & Grune, T. (2008) · IUBMB Life · doi:10.1002/iub.114 · Cited by 162
Targeting the DNA Damage Response in Cancer
Ljungman, M. E. (2009) · Chemical Reviews · doi:10.1021/cr900047g · Cited by 164
Large-Scale Identification of c-MYC-Associated Proteins Using a Combined TAP/MudPIT Approach
Koch, H., Zhang, R., Verdoodt, B., Bailey, A. O., Zhang, C.-D., Yates, J. R., Menssen, A., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.2.3742 · Cited by 162
Visualization and targeted disruption of protein interactions in living cells
Herce, H. D., Deng, W., Helma, J., Leonhardt, H., & Cardoso, M. C. (2013) · Nature Communications · doi:10.1038/ncomms3660 · Cited by 166
Senescence and senotherapeutics: a new field in cancer therapy
Myrianthopoulos, V., Evangelou, K., Vasileiou, P. V. S., Cooks, T., Vassilakopoulos, T. P., Pangalis, G. A., Kouloukoussa, M., Kittas, C., Georgakilas, A. G., & Gorgoulis, V. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.006 · Cited by 160
Regulation of p53 by the Ubiquitin-conjugating Enzymes UbcH5B/C in Vivo
Saville, M. K., Sparks, A., Xirodimas, D. P., Wardrop, J., Stevenson, L. F., Bourdon, J.-C., Woods, Y. L., & Lane, D. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403362200 · Cited by 158
Efficient Room‐Temperature Synthesis of Tri‐ and Tetrasubstituted Imidazoles Catalyzed by ZrCl4
Sharma, G. V. M., Jyothi, Y., & Lakshmi, P. S. (2006) · Synthetic Communications · doi:10.1080/00397910600773825 · Cited by 161
High Mitochondrial Priming Sensitizes hESCs to DNA-Damage-Induced Apoptosis
Liu, J. C., Guan, X., Ryan, J. A., Rivera, A. G., Mock, C., Agarwal, V., Letai, A. G., Lerou, P. H., & Lahav, G. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.07.018 · Cited by 158
Differentiation therapy of acute myeloid leukemia: past, present and future
Petrie, K. R., Zelent, A., & Waxman, S. (2009) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283257aee · Cited by 161
p53-Responsive miR-194 Inhibits Thrombospondin-1 and Promotes Angiogenesis in Colon Cancers
Sundaram, P., Hultine, S., Smith, L. M., Dews, M., Fox, J. L., Biyashev, D., Schelter, J. M., Huang, Q., Cleary, M. A., Volpert, O. V., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1124 · Cited by 161
Metadata
- Authors
- Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., & Liu, E. A.
- Affiliations
- Department of Discovery Oncology, Roche Research Center, Hoffmann–La Roche, Inc., Nutley, NJ 07110, USA.
- Corresponding author
- Vassilev, Lyubomir T.
- Venue
- Science
- Published
- 2004-02-06
- Volume
- 303
- Issue
- 5659
- Pages
- 844-848
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2097933346
- Cited by
- 4,661
- References
- 21
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 169 · 2023: 203 · 2022: 204 · 2021: 199 · 2020: 226 · 2019: 212 · 2018: 216 · 2017: 209 · 2016: 258 · 2015: 248 · 2014: 296 · 2013: 273 · 2012: 265
- FWCI
- 83.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- MDM2, p53, small molecule antagonists, p53 stabilization, p53-MDM2 interaction, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts, crystal structure
- MeSH terms
- Animals, Binding Sites, Cell Cycle, Cell Division, Cell Line, Cell Survival, Crystallization, Dose-Response Relationship, Drug, Humans, Imidazoles, Mice, Nude, Models, Molecular, Molecular Weight, Neoplasm Transplantation, Neoplasms, Experimental, Nuclear Proteins, Phosphorylation, Piperazines, Protein Conformation, Proto-Oncogene Proteins, Stereoisomerism, Transplantation, Heterologous, Gene Expression, Genes, p53, Tumor Suppressor Protein p53, Cyclins, Apoptosis, Crystallography, X-Ray, NIH 3T3 Cells, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21, Mice, Proto-Oncogene Proteins c-mdm2, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
